Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139


Efficacy of Withania somnifera chemotypes NMITLI - 101R, 118R and Withaferin A against experimental visceral leishmaniasis.

Tripathi CD, Gupta R, Kushawaha PK, Mandal C, Misra Bhattacharya S, Dube A.

Parasite Immunol. 2014 Jun;36(6):253-65. doi: 10.1111/pim.12112.


Withania somnifera chemotypes NMITLI 101R, NMITLI 118R, NMITLI 128R and withaferin A protect Mastomys coucha from Brugia malayi infection.

Kushwaha S, Soni VK, Singh PK, Bano N, Kumar A, Sangwan RS, Misra-Bhattacharya S.

Parasite Immunol. 2012 Apr;34(4):199-209. doi: 10.1111/j.1365-3024.2012.01352.x.


Chemotypical variations in Withania somnifera lead to differentially modulated immune response in BALB/c mice.

Kushwaha S, Roy S, Maity R, Mallick A, Soni VK, Singh PK, Chaurasiya ND, Sangwan RS, Misra-Bhattacharya S, Mandal C.

Vaccine. 2012 Feb 1;30(6):1083-93. doi: 10.1016/j.vaccine.2011.12.031. Epub 2011 Dec 17.


Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.

Gupta R, Kushawaha PK, Samant M, Jaiswal AK, Baharia RK, Dube A.

J Antimicrob Chemother. 2012 Feb;67(2):440-3. doi: 10.1093/jac/dkr485. Epub 2011 Nov 25.


Studies on the protective and immunomodulatory efficacy of Withania somnifera along with cisplatin against experimental visceral leishmaniasis.

Sachdeva H, Sehgal R, Kaur S.

Parasitol Res. 2013 Jun;112(6):2269-80. doi: 10.1007/s00436-013-3387-2. Epub 2013 Mar 22.


Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.

Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A.

J Immunol. 2011 Dec 15;187(12):6417-27. doi: 10.4049/jimmunol.1102081. Epub 2011 Nov 11.


Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.

Khare P, Jaiswal AK, Tripathi CD, Joshi S, Sundar S, Dube A.

Parasitol Res. 2014 Mar;113(3):851-62. doi: 10.1007/s00436-013-3716-5. Epub 2013 Dec 27.


Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis.

Kushawaha PK, Gupta R, Tripathi CD, Sundar S, Dube A.

PLoS One. 2012;7(4):e35670. doi: 10.1371/journal.pone.0035670. Epub 2012 Apr 23.


Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.

Gupta R, Kumar V, Kushawaha PK, Tripathi CP, Joshi S, Sahasrabuddhe AA, Mitra K, Sundar S, Siddiqi MI, Dube A.

PLoS One. 2014 Jan 24;9(1):e86073. doi: 10.1371/journal.pone.0086073. eCollection 2014.


Protection against experimental visceral leishmaniasis by immunostimulation with herbal drugs derived from Withania somnifera and Asparagus racemosus.

Kaur S, Chauhan K, Sachdeva H.

J Med Microbiol. 2014 Oct;63(Pt 10):1328-38. doi: 10.1099/jmm.0.072694-0. Epub 2014 Jul 31.


Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.

Kumari S, Samant M, Misra P, Khare P, Sisodia B, Shasany AK, Dube A.

Vaccine. 2008 Oct 23;26(45):5700-11. doi: 10.1016/j.vaccine.2008.08.021. Epub 2008 Aug 30.


A standardized root extract of Withania somnifera and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice.

Malik F, Singh J, Khajuria A, Suri KA, Satti NK, Singh S, Kaul MK, Kumar A, Bhatia A, Qazi GN.

Life Sci. 2007 Mar 27;80(16):1525-38. Epub 2007 Jan 25.


Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.

Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, Sahasrabuddhe AA, Dube A.

J Immunol. 2009 Jul 1;183(1):470-9. doi: 10.4049/jimmunol.0900265.


Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis.

Datta S, Manna M, Khanra S, Ghosh M, Bhar R, Chakraborty A, Roy S.

Parasitol Res. 2012 Jul;111(1):361-9. doi: 10.1007/s00436-012-2847-4. Epub 2012 Mar 23.


Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.

Shivahare R, Vishwakarma P, Parmar N, Yadav PK, Haq W, Srivastava M, Gupta S, Kar S.

PLoS One. 2014 Apr 14;9(4):e94596. doi: 10.1371/journal.pone.0094596. eCollection 2014.


Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis.

Kushawaha PK, Gupta R, Tripathi CD, Khare P, Jaiswal AK, Sundar S, Dube A.

PLoS One. 2012;7(9):e45766. doi: 10.1371/journal.pone.0045766. Epub 2012 Sep 24.


115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.

Choudhury R, Das P, De T, Chakraborti T.

Immunobiology. 2013 Jan;218(1):114-26. doi: 10.1016/j.imbio.2012.02.008. Epub 2012 Feb 16.


Tinospora cordifolia as a protective and immunomodulatory agent in combination with cisplatin against murine visceral leishmaniasis.

Sachdeva H, Sehgal R, Kaur S.

Exp Parasitol. 2014 Feb;137:53-65. doi: 10.1016/j.exppara.2013.12.006. Epub 2013 Dec 25.

Items per page

Supplemental Content

Write to the Help Desk